Find, compare & contact
Diprenorphine
API Manufacturers & Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Looking for Diprenorphine API 14357-78-9?
- Description:
- Here you will find a list of producers, manufacturers and distributors of Diprenorphine. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
- API | Excipient name:
- Diprenorphine
- Synonyms:
- Diprenorfin , Diprenorphine
- Cas Number:
- 14357-78-9
- DrugBank number:
- DB01548
- Unique Ingredient Identifier:
- 1F0L5N25ZZ
General Description:
Diprenorphine, identified by CAS number 14357-78-9, is a notable compound with significant therapeutic applications. A narcotic antagonist similar in action to naloxone. It is used to remobilize animals after etorphine neuroleptanalgesia and is considered a specific antagonist to etorphine.
Indications:
This drug is primarily indicated for: Diprenorphine is indicated to reverse the effects of powerful opioids including etorphine and carfentanil, often used for tranquilizing large animals. This drug is not approved for use in humans. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.
Mechanism of Action:
Diprenorphine functions by: Diprenorphine binds approximately equally to the three subtypes of opioid receptorsand antagonizes them. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.
Classification:
Diprenorphine belongs to the class of organic compounds known as phenanthrenes and derivatives. These are polycyclic compounds containing a phenanthrene moiety, which is a tricyclic aromatic compound with three non-linearly fused benzene, classified under the direct parent group Phenanthrenes and derivatives. This compound is a part of the Organic compounds, falling under the Benzenoids superclass, and categorized within the Phenanthrenes and derivatives class, specifically within the None subclass.
Categories:
Diprenorphine is categorized under the following therapeutic classes: Alkaloids, Central Nervous System Agents, Heterocyclic Compounds, Fused-Ring, Morphinans, Opiate Alkaloids, Opioid Antagonists, Peripheral Nervous System Agents, Phenanthrenes, Sensory System Agents. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.
Diprenorphine is a type of Central Nervous System Agents
Central Nervous System (CNS) Agents are a crucial category of pharmaceutical Active Pharmaceutical Ingredients (APIs) that specifically target the central nervous system. The CNS encompasses the brain and spinal cord, playing a vital role in regulating and controlling various bodily functions, including cognition, movement, emotions, and sensory perception. These agents are designed to interact with specific receptors, enzymes, or ion channels within the CNS to modulate neural activity and restore normal functioning.
CNS agents comprise a diverse range of pharmaceutical APIs, including analgesics, anesthetics, antipsychotics, sedatives, hypnotics, anti-epileptics, and antidepressants. Each subcategory addresses distinct neurological disorders and conditions. For instance, analgesics alleviate pain by targeting receptors in the brain and spinal cord, while antipsychotics are employed to manage psychosis symptoms in mental illnesses such as schizophrenia.
The development of CNS agents involves rigorous research, molecular modeling, and extensive clinical trials to ensure safety, efficacy, and specific target engagement. Pharmaceutical companies invest significant resources in identifying novel drug targets, synthesizing new compounds, and optimizing their pharmacological properties. These agents undergo rigorous regulatory evaluations and must adhere to stringent quality standards and guidelines.
Given the prevalence of CNS disorders globally, the market demand for effective CNS agents is substantial. The development of innovative CNS APIs not only improves patient outcomes but also provides valuable commercial opportunities for pharmaceutical companies. Continued advancements in CNS agent research and development hold the promise of groundbreaking therapies that can improve the quality of life for individuals affected by neurological conditions.
